Bronchiectasis

Bronchiectasis is a chronic respiratory condition characterized by permanent, irreversible dilation and structural damage to the bronchi, the medium-sized airways that branch from the trachea to deliver air throughout the lungs. This pathological widening of the airways results from destruction of the elastic and muscular components of the bronchial walls, leaving them weakened, distorted, and unable to function normally. The dilated bronchi lose their ability to effectively clear mucus and debris, creating a self-perpetuating cycle of mucus accumulation, bacterial colonization, recurrent infection, and progressive airway damage. Unlike acute respiratory infections that resolve with treatment, bronchiectasis represents permanent structural changes that require lifelong management to control symptoms and slow disease progression.

The development of bronchiectasis follows a pattern known as the vicious cycle hypothesis, where initial airway injury from infection, inflammation, or structural abnormality impairs normal clearance mechanisms. This impairment leads to mucus stasis, which promotes bacterial growth and chronic infection. The ongoing infection and associated inflammatory response cause further damage to the airway walls, worsening the dilation and clearance dysfunction. This cycle continues unless interrupted by treatment, progressively expanding the extent and severity of airway involvement. Understanding this pathophysiology guides treatment approaches that target multiple points in the cycle including infection control, inflammation reduction, and mucus clearance enhancement.

Bronchiectasis in dogs can develop as a consequence of various underlying conditions or may be present from birth in dogs with primary ciliary dyskinesia, a genetic disorder affecting the cilia that normally sweep mucus out of the airways. Acquired bronchiectasis most commonly results from severe or repeated respiratory infections, particularly those occurring in young dogs before their airways have fully developed. Chronic inflammatory conditions, foreign body aspiration with prolonged airway obstruction, smoke inhalation injury, and immune deficiencies can all lead to the bronchial damage that results in bronchiectasis. The condition may be localized to specific lung lobes when resulting from focal injury or infection, or diffuse when caused by systemic conditions like ciliary dyskinesia.

The clinical significance of bronchiectasis lies in its chronic nature and the ongoing management challenges it presents for affected dogs and their owners. Dogs with bronchiectasis typically experience persistent or recurrent coughing, exercise intolerance, and intermittent respiratory infections that can significantly impact quality of life. While bronchiectasis cannot be cured, appropriate management can substantially improve symptoms, reduce infection frequency, and slow progression of airway damage. Working closely with a veterinarian to develop and maintain an individualized management plan helps dogs with bronchiectasis live more comfortable lives despite their chronic condition.

Severe or recurrent respiratory infections represent the most common cause of acquired bronchiectasis in dogs, particularly when infections occur during puppyhood when the airways are still developing. Bacterial pneumonia, viral respiratory infections complicated by secondary bacterial invasion, and other lower respiratory tract infections can cause sufficient airway damage to initiate the bronchiectatic process. Bordetella bronchiseptica infection, particularly severe cases affecting young puppies, has been specifically associated with bronchiectasis development. The severity and duration of infection correlate with the likelihood of permanent airway damage, with prolonged or incompletely treated infections carrying higher risk than brief, effectively treated episodes.

Primary ciliary dyskinesia is an inherited disorder that causes bronchiectasis through impaired mucociliary clearance rather than direct airway damage. Dogs with this condition have defective cilia, the microscopic hair-like projections lining the respiratory tract that normally beat in coordinated waves to move mucus toward the throat for clearance. When cilia cannot function properly, mucus accumulates in the airways, leading to chronic bacterial colonization, recurrent infection, and progressive airway damage. Primary ciliary dyskinesia affects multiple organ systems where ciliary function is important, and affected dogs often have additional abnormalities including chronic rhinosinusitis and male infertility due to immotile sperm. Some affected dogs have situs inversus, where the internal organs are mirror-reversed from their normal positions.

Foreign body aspiration can cause localized bronchiectasis when inhaled material lodges in a bronchus and remains there long enough to cause chronic inflammation and infection distal to the obstruction. Plant material, particularly grass awns, is a common aspirated foreign body in dogs that can migrate through airways and cause persistent local damage. The bronchiectasis that develops from foreign body aspiration is typically limited to the lung lobe or segment supplied by the affected bronchus, in contrast to the more diffuse involvement seen with systemic conditions. Complete removal of the foreign body is essential but may not reverse already-established bronchiectasis.

Chronic inflammatory airway conditions can progress to bronchiectasis if inflammation persists long enough to cause structural damage to the bronchial walls. Chronic bronchitis, allergic airway disease, and other conditions causing prolonged airway inflammation may eventually lead to bronchiectatic changes, particularly when inadequately controlled. Smoke inhalation injury, whether from fires, cigarette smoke exposure, or other sources, can cause both acute airway damage and chronic changes that predispose to bronchiectasis. Immunodeficiency conditions that impair the ability to clear respiratory infections effectively increase the risk of bronchiectasis development from recurrent or persistent infections.

Congenital abnormalities and developmental defects occasionally cause bronchiectasis present from birth or early life. Kartagener syndrome, a specific form of primary ciliary dyskinesia associated with situs inversus and sinusitis, causes bronchiectasis through ciliary dysfunction. Other developmental abnormalities affecting bronchial structure or function may predispose to early bronchiectasis development. Identifying congenital causes is important for genetic counseling if breeding is being considered, as these conditions are typically inherited. Dogs with congenital bronchiectasis often show symptoms from a young age and may have more severe or rapidly progressive disease than those with acquired forms.

Chronic productive coughing represents the hallmark symptom of bronchiectasis in dogs, reflecting the ongoing accumulation of mucus in the dilated, poorly clearing airways. This cough typically produces sputum, though owners may not observe expectoration if dogs swallow their respiratory secretions as most dogs do. The cough character is often described as moist, harsh, or rattling, distinguishing it from the dry hacking cough of some other respiratory conditions. Coughing may occur throughout the day but is often most noticeable in the morning when secretions that accumulated overnight need to be cleared, or following periods of rest after which the dog becomes active. The chronic nature of the cough, persisting for months to years with variable intensity, characterizes bronchiectasis and distinguishes it from acute respiratory infections.

Respiratory symptoms beyond coughing develop as bronchiectasis progresses and increasingly impairs lung function. Exercise intolerance becomes apparent as affected dogs tire more quickly during activity than healthy dogs or show reluctance to engage in previously enjoyed activities. Some dogs develop noisy breathing or audible wheezing, particularly during exertion or when experiencing flare-ups of their condition. Increased respiratory rate and effort may be observed, especially with more advanced disease. Dogs may prefer certain body positions that ease breathing or show discomfort when lying flat. Gradually progressive worsening of respiratory function over months to years is typical of bronchiectasis, though the rate of progression varies considerably between individuals.

Recurrent respiratory infections represent a characteristic feature of bronchiectasis that significantly impacts affected dogs and their owners. The mucus-filled, damaged airways provide an ideal environment for bacterial growth, and affected dogs typically experience episodic worsening of symptoms associated with acute bacterial infection superimposed on their chronic disease. During these exacerbations, coughing increases in frequency and intensity, sputum production may increase or change character, fever may develop, and dogs often show decreased appetite and lethargy. Some dogs experience frequent exacerbations requiring repeated courses of antibiotic therapy, while others have less frequent episodes with longer periods of relative stability between them.

Systemic symptoms may accompany the respiratory signs, particularly during infection exacerbations. Weight loss can occur in dogs with advanced bronchiectasis due to the metabolic demands of chronic infection and inflammation combined with reduced appetite during flare-ups. Lethargy or decreased activity may be present chronically or may worsen during exacerbations. Some dogs develop a gradual change in body condition with muscle wasting despite adequate caloric intake. Signs related to comorbid conditions may be present, such as chronic nasal discharge in dogs with primary ciliary dyskinesia affecting the upper respiratory tract as well as the lower airways.

Symptom severity varies considerably among dogs with bronchiectasis, ranging from mild chronic cough with infrequent exacerbations to severe respiratory impairment significantly limiting quality of life. The extent and distribution of bronchiectatic changes influences symptom severity, with diffuse disease typically causing more symptoms than localized involvement. The presence and nature of bacterial colonization affects exacerbation frequency and severity. Comorbid conditions including other respiratory diseases, cardiac disease, or systemic illness can worsen symptoms and complicate management. Individual dogs may show relatively stable symptoms over years or may experience progressive deterioration despite treatment.

Emergency symptoms requiring immediate veterinary attention include severe respiratory distress, cyanosis, collapse, or high fever with marked worsening of respiratory status. While bronchiectasis itself is a chronic condition managed over time, acute exacerbations can progress to severe pneumonia or respiratory failure if not appropriately treated. Dogs with known bronchiectasis who develop significantly worsening symptoms should receive prompt veterinary evaluation to assess whether hospitalization and intensive treatment are needed. Sudden deterioration in a previously stable patient may indicate severe exacerbation, pneumonia development, or complications such as pneumothorax.

Diagnosis of bronchiectasis requires demonstration of bronchial dilation through imaging studies combined with clinical history and examination findings consistent with chronic lower respiratory disease. The diagnostic process also aims to identify underlying causes that may be treatable and to assess disease severity to guide management decisions. A thorough approach to diagnosis provides the foundation for developing an effective long-term management plan tailored to the individual patient.

Clinical history and physical examination provide important information supporting bronchiectasis diagnosis. A history of chronic productive cough persisting for months or longer, recurrent respiratory infections, or known predisposing conditions such as severe puppy pneumonia raises suspicion for bronchiectasis. Physical examination typically reveals abnormal lung sounds on auscultation, including crackles, wheezes, or increased bronchial sounds over affected lung regions. Tachypnea, increased respiratory effort, and poor body condition may be present in more severe cases. Examination should also assess for signs of primary ciliary dyskinesia, including chronic nasal discharge suggesting rhinosinusitis and, in rare cases, the abnormal heart sounds that might accompany situs inversus.

Chest radiographs represent the first-line imaging modality for evaluating dogs with suspected bronchiectasis. Radiographic findings include thickened bronchial walls appearing as parallel linear opacities known as tram lines, dilated bronchi that may appear as ring-shaped opacities when viewed in cross-section, and loss of normal tapering of bronchi toward the lung periphery. Peribronchial infiltrates and patchy alveolar patterns may accompany bronchiectatic changes, particularly during infection exacerbations. The distribution of changes provides information about whether disease is localized or diffuse. However, radiographs may underestimate the extent of bronchiectasis, particularly early in the disease course, and normal radiographs do not exclude the diagnosis.

Computed tomography provides more sensitive and detailed evaluation of bronchial structure than standard radiography and represents the gold standard for bronchiectasis diagnosis in both human and veterinary medicine. CT clearly demonstrates bronchial dilation, wall thickening, and the characteristic signet ring sign where a dilated bronchus appears larger than the adjacent pulmonary artery. CT also allows accurate assessment of disease distribution and extent, identification of mucus plugging, and detection of associated abnormalities such as atelectasis or pneumonia. While CT requires anesthesia, it provides invaluable information for confirming diagnosis and characterizing disease in dogs with suspected bronchiectasis.

Additional diagnostic testing helps identify underlying causes and guides management decisions. Bronchoalveolar lavage collects samples from the lower airways for cytology and bacterial culture, characterizing the inflammatory response and identifying colonizing or infecting organisms. Cytology typically shows neutrophilic inflammation with or without intracellular bacteria. Culture results guide antibiotic selection for treating exacerbations. Testing for primary ciliary dyskinesia through specialized evaluation of ciliary structure and function may be indicated in young dogs with bronchiectasis, particularly those with chronic upper respiratory signs or other suggestive features. Blood work assesses overall health status and screens for conditions that might affect management.

Treatment of bronchiectasis focuses on controlling symptoms, treating infections, promoting airway clearance, and slowing disease progression, as the structural airway damage cannot be reversed. A multimodal management approach addressing multiple aspects of the disease process typically achieves better results than any single intervention alone. Treatment plans should be individualized based on disease severity, exacerbation frequency, identified pathogens, and patient-specific factors. Long-term commitment to ongoing management is required, as bronchiectasis is a chronic condition requiring lifelong attention.

Antibiotic therapy plays a central role in managing bronchiectasis, used both for treating acute exacerbations and in some cases for long-term suppression of chronic infection. During exacerbations characterized by increased coughing, purulent sputum, fever, or worsening respiratory status, antibiotic courses targeting identified or likely pathogens are administered for two to four weeks or longer. Antibiotic selection is ideally guided by culture and sensitivity results from bronchoalveolar lavage or expectorated sputum when available. Common pathogens include Bordetella bronchiseptica, Pasteurella species, Streptococcus species, and various opportunistic organisms. For dogs with frequent exacerbations despite standard management, chronic suppressive antibiotic therapy using intermittent or continuous low-dose regimens may reduce exacerbation frequency, though this approach requires careful consideration of resistance development risk.

Airway clearance techniques help remove accumulated mucus from the dilated bronchi that cannot clear secretions normally. Nebulization with saline delivers moisture directly to the airways, hydrating thick mucus and facilitating its mobilization. Coupage, rhythmic percussion on the chest wall, helps loosen adherent secretions and promotes their movement toward the central airways where coughing can clear them. These techniques are particularly valuable when performed before activity or periods that typically provoke coughing, allowing more effective secretion clearance. Teaching owners to perform nebulization and coupage at home enables regular airway clearance sessions that would not be practical if veterinary visits were required for each treatment.

Bronchodilators may provide symptomatic benefit in some dogs with bronchiectasis by relaxing airway smooth muscle and improving airflow through narrowed passages. Methylxanthines such as theophylline or aminophylline have both bronchodilator and mild anti-inflammatory effects that may be beneficial. Beta-agonist bronchodilators like terbutaline or albuterol can be administered orally or through nebulization for more direct airway delivery. The degree of bronchodilator responsiveness varies among patients, and clinical assessment of treatment effect guides decisions about continued use. Bronchodilators are most useful when bronchospasm contributes significantly to airflow limitation alongside the fixed structural abnormalities of bronchiectasis.

Anti-inflammatory therapy may help modulate the chronic inflammation that drives ongoing airway damage in bronchiectasis. Inhaled corticosteroids delivered through metered-dose inhalers with spacer devices designed for dogs can reduce airway inflammation with minimal systemic effects. Systemic corticosteroids may be used short-term during severe exacerbations but are generally avoided for long-term management due to side effects and potential immunosuppression that could increase infection risk. Other anti-inflammatory approaches including omega-3 fatty acid supplementation may provide modest benefit as adjunctive therapy.

Surgical intervention may be considered for dogs with localized bronchiectasis limited to one or two lung lobes when medical management fails to adequately control symptoms. Lung lobectomy removes the affected tissue, potentially curing or substantially improving the condition if remaining lung tissue is healthy. Surgery is not appropriate for diffuse bronchiectasis affecting multiple lobes, as insufficient normal lung tissue would remain. Careful preoperative assessment including CT imaging determines whether surgical candidacy exists. Dogs must be medically stabilized and infection controlled before surgery to optimize outcomes. When appropriate, surgical resection of localized bronchiectasis can provide excellent long-term results.

The concept of recovery in bronchiectasis differs from that of acute conditions, as the structural airway damage is permanent and the focus shifts to chronic disease management rather than cure. However, appropriate treatment can result in significant clinical improvement that might be considered a form of recovery from the perspective of quality of life and functional status. Dogs with bronchiectasis that is well-managed can experience substantial reductions in coughing frequency and severity, fewer infection exacerbations, improved exercise tolerance, and better overall comfort compared to their untreated state.

Initial response to treatment typically occurs over weeks to months as chronic infection is controlled and inflammation decreases. Dogs starting comprehensive bronchiectasis management often show improvement in coughing, appetite, and activity level within the first few weeks of treatment as acute infection components respond to antibiotics. More gradual improvement in exercise tolerance and reduction in exacerbation frequency may continue over subsequent months as the airways become less heavily colonized and inflammatory burden decreases. Setting appropriate expectations that improvement will be gradual and ongoing rather than dramatic and immediate helps maintain owner commitment to long-term management.

Factors affecting the degree of clinical improvement achievable include the extent and severity of bronchiectasis, the presence and nature of underlying causes, the chronicity of disease before treatment initiation, and the consistency of management implementation. Dogs with localized disease affecting one or two lobes typically achieve better control than those with diffuse involvement. When underlying causes can be addressed, such as removing retained foreign bodies or managing contributing conditions, outcomes improve. Dogs whose bronchiectasis is identified and managed relatively early in the disease course may fare better than those presenting after years of progressive damage. Consistent implementation of prescribed management including medications, nebulization, and other therapies significantly affects outcomes.

Long-term prognosis for dogs with bronchiectasis varies considerably but is generally guarded for complete resolution while being fair to good for quality of life with appropriate management. Some dogs live comfortable lives for years with well-controlled bronchiectasis, experiencing only occasional mild exacerbations. Others have more severe or progressive disease that significantly impacts quality of life despite treatment. Dogs with primary ciliary dyskinesia face lifelong challenges but can achieve meaningful quality of life with comprehensive management. Regular reassessment allows treatment adjustment as the disease and response to therapy evolve over time.

Prevention of bronchiectasis focuses primarily on avoiding or promptly treating the conditions that cause airway damage, as well as genetic screening for inherited forms. While not all cases can be prevented, attention to respiratory health throughout a dog's life, particularly during the vulnerable puppy period, reduces the likelihood of developing this chronic condition. Understanding risk factors enables targeted prevention efforts for dogs at elevated risk.

Prompt and complete treatment of respiratory infections, especially in puppies and young dogs, represents the most important preventable cause of acquired bronchiectasis. Ensuring puppies receive appropriate vaccination against respiratory pathogens including Bordetella bronchiseptica, canine parainfluenza, and other agents reduces infection risk. When respiratory infections do occur, seeking veterinary care promptly and completing the full prescribed course of treatment helps prevent the prolonged or severe infections that cause airway damage. Avoiding exposure to known respiratory pathogens when possible and maintaining good ventilation in kennel and household environments reduces infection acquisition risk.

Genetic counseling and breeding practices can reduce the incidence of primary ciliary dyskinesia, the inherited cause of bronchiectasis. Dogs identified with this condition should not be bred, and affected littermates and parents should be considered carriers for breeding decisions. Genetic testing may be available for certain breeds with higher prevalence of primary ciliary dyskinesia. Puppy buyers should research breed-specific health issues and purchase from breeders who prioritize respiratory health and conduct appropriate health screening. Dogs from breeds or lines with known ciliary dyskinesia should receive thorough respiratory evaluation if any symptoms develop.

Nutritional support for respiratory health and immune function helps dogs resist and recover from respiratory infections that could cause airway damage. Providing complete and balanced nutrition appropriate for life stage supports overall health and immune competence. Maintaining healthy body weight reduces respiratory workload. Avoiding obesity, which compounds respiratory challenges, is particularly important for breeds predisposed to respiratory conditions. Supplementation with omega-3 fatty acids may provide anti-inflammatory benefits that support respiratory health.

Environmental management reduces exposure to respiratory irritants that can damage airways or compound infectious injury. Eliminating smoke exposure, whether from cigarettes, fireplaces, or outdoor sources, protects the respiratory tract. Reducing dust, mold, and other airborne irritants through appropriate housekeeping and air filtration supports respiratory health. Avoiding exposure to chemical fumes, aerosol sprays, and strong fragrances in the dog's environment reduces airway irritation. Maintaining good ventilation in living spaces promotes healthy airways. These measures benefit all dogs but are particularly important for those with any existing respiratory vulnerability or predisposing conditions.

Daily management of dogs with bronchiectasis involves consistent implementation of prescribed therapies combined with lifestyle modifications that support respiratory health and quality of life. Owners play an essential role in bronchiectasis management, as many aspects of care occur at home between veterinary visits. Developing routines that incorporate necessary treatments while maintaining normalcy helps dogs and owners adapt to living with this chronic condition.

Medication administration requires careful attention to ensure dogs receive all prescribed treatments appropriately. Antibiotic courses must be completed as prescribed, whether for treating acute exacerbations or as part of chronic suppressive therapy if indicated. Bronchodilators should be given on schedule to maintain consistent airway dilation. Any inhaled medications delivered through spacer devices require proper technique to ensure effective drug delivery. Keeping a medication log helps track doses and ensures none are missed. Organizing medications and establishing reminder systems supports consistent administration.

Airway clearance therapies should be performed regularly as part of the daily management routine. Nebulization sessions, typically lasting ten to fifteen minutes and performed one to three times daily depending on disease severity and veterinary recommendations, help hydrate airway secretions for easier clearance. Coupage performed after nebulization enhances secretion mobilization. The timing of airway clearance relative to meals, activity, and rest periods can be optimized based on when the dog naturally coughs most productively. Owners should receive instruction from the veterinary team on proper technique and be comfortable performing these therapies at home.

Environmental modifications support respiratory comfort for dogs with bronchiectasis. Maintaining excellent air quality through elimination of smoke, reduction of dust and allergens, and use of air purifiers with HEPA filtration reduces airway irritation. Appropriate humidity levels prevent both excessively dry air that thickens secretions and excessive humidity that promotes microbial growth. Temperature control avoiding extreme cold or heat that can trigger bronchospasm improves respiratory comfort. Creating comfortable resting areas with good air circulation supports the dog's respiratory function.

Quality of life considerations balance disease management with maintaining enjoyable activities and social connections. Dogs with bronchiectasis can often participate in moderate activities appropriate to their respiratory capacity, maintaining physical conditioning and mental wellbeing. Adjusting exercise intensity and duration based on the dog's tolerance and current respiratory status allows activity without excessive respiratory stress. Mental stimulation through training, puzzle toys, and social interaction maintains quality of life even when physical activity must be limited. Regular assessment of what activities the dog enjoys and tolerates helps maintain quality of life.

Ongoing monitoring enables detection of exacerbations or disease progression requiring veterinary attention. Owners should watch for increased coughing frequency or severity, changes in sputum character, decreased appetite or energy, and signs of respiratory distress that might indicate developing infection. Maintaining a symptom diary helps identify patterns and provides useful information for veterinary consultations. Regular veterinary check-ups allow professional assessment of disease status and treatment effectiveness. Understanding when home management is sufficient versus when veterinary evaluation is needed helps ensure appropriate care intensity while avoiding unnecessary visits.

Certain dog breeds face elevated risk of bronchiectasis due to genetic predisposition to primary ciliary dyskinesia or other factors that increase susceptibility to the conditions causing acquired bronchiectasis. Breed associations help identify dogs who may benefit from enhanced monitoring for respiratory symptoms and prompt intervention if problems develop. Understanding breed-related risk factors supports informed breeding decisions and appropriate health screening.

Breeds with documented increased prevalence of primary ciliary dyskinesia include English Springer Spaniels, Bichon Frises, Border Collies, Bull Mastiffs, Chow Chows, English Cocker Spaniels, English Setters, Golden Retrievers, Newfoundlands, Old English Sheepdogs, and Shar-Peis. These breeds should be monitored for signs of ciliary dysfunction including chronic nasal discharge from puppyhood, recurrent respiratory infections, and chronic cough. Dogs of these breeds presenting with compatible symptoms should be evaluated for primary ciliary dyskinesia through specialized testing. Affected dogs should not be bred, and relatives should be considered carriers when making breeding decisions.

Brachycephalic breeds may face increased risk of lower respiratory complications including bronchiectasis due to their compromised upper airway anatomy and associated respiratory challenges. While bronchiectasis is not specifically increased in these breeds from genetic factors, the chronic respiratory stress and increased infection susceptibility associated with brachycephalic obstructive airway syndrome may predispose to airway damage. English Bulldogs, French Bulldogs, Pugs, and other brachycephalic breeds with significant airway compromise benefit from careful respiratory monitoring and prompt treatment of any respiratory infections.

Screening recommendations for at-risk breeds include thorough respiratory evaluation of any dog with chronic respiratory symptoms, consideration of genetic testing when available for ciliary dyskinesia, and chest imaging to assess for bronchiectasis when clinical suspicion exists. Breeders of affected breeds should be educated about primary ciliary dyskinesia and encouraged to screen breeding dogs and avoid breeding affected animals. Puppy buyers should research respiratory health in their chosen breed and select breeders who prioritize respiratory health in their breeding programs. Early identification of bronchiectasis allows management to begin before disease progresses significantly.

Several conditions frequently co-occur with bronchiectasis or share overlapping features that require differentiation through careful diagnostic evaluation. Understanding these relationships supports comprehensive patient assessment and ensures that comorbid conditions receive appropriate management alongside bronchiectasis treatment. Recognition of related conditions also helps identify underlying causes of bronchiectasis that may be treatable.

Chronic bronchitis frequently co-occurs with bronchiectasis and may precede or accompany bronchiectatic changes. Both conditions cause chronic cough and airway inflammation, and distinguishing between them can be challenging. Chronic bronchitis involves airway inflammation without the structural dilation defining bronchiectasis, though prolonged untreated chronic bronchitis may eventually lead to bronchiectatic changes. Dogs with both conditions require management addressing both the inflammatory component and the structural abnormalities. Treatment approaches overlap considerably, though the presence of bronchiectasis indicates irreversible changes requiring lifelong management expectations.

Primary ciliary dyskinesia, when present as the underlying cause of bronchiectasis, produces additional manifestations beyond lung disease that require recognition and management. Chronic rhinosinusitis with persistent nasal discharge is nearly universal in affected dogs and may be the presenting complaint that leads to bronchiectasis discovery. Male dogs with primary ciliary dyskinesia typically have immotile sperm causing infertility. Situs inversus, the mirror-image reversal of internal organ positions, occurs in approximately half of affected dogs and should be identified if present as it affects surgical planning should any abdominal procedures be needed. Recognition of the syndrome guides genetic counseling and prevents futile breeding attempts with affected males.

Conditions causing similar symptoms must be differentiated from bronchiectasis to ensure appropriate treatment. Chronic bronchitis without bronchiectasis may respond to management that would be insufficient for bronchiectasis. Allergic airway disease presents with chronic cough and airway inflammation but has different underlying pathophysiology and treatment requirements. Neoplasia affecting the airways can produce chronic respiratory symptoms and must be excluded through appropriate imaging. Cardiac disease causing cough due to left atrial enlargement or pulmonary edema may mimic respiratory disease and requires cardiac evaluation to identify. Accurate differentiation ensures that dogs receive appropriate, targeted treatment rather than generic respiratory management that may be suboptimal for their specific condition.